Lennox-Gastaut Syndrome Across the Continuum: Optimizing Seizure and Non-Seizure Outcomes from Pediatrics to Adulthood

Clinical Conversations in Action: Expert Panels and Case-Driven Breakout Sessions
earn up to 1.0 ACCME credit
Register
About The Program
Overview
Learning Objectives
CME Information
Faculty and Disclosures
Instructions

Program Overview

Despite advancements in care, patients with Lennox-Gastaut Syndrome (LGS) continue to experience delayed diagnoses, inconsistent access to emerging therapies, and significant unmet needs related to seizure and non-seizure outcomes. These challenges are compounded by a lack of coordinated, multidisciplinary care and limited caregiver engagement in treatment planning.

To address these critical gaps in care, Lennox-Gastaut Syndrome Across the Continuum: Optimizing Seizure and Non-Seizure Outcomes from Pediatrics to Adulthood delivers a CME-certified, virtual learning experience designed to reflect real-world clinical challenges. This interactive program engages healthcare providers through expert-led discussions, real patient documentary vignettes, and facilitated case-based breakout sessions—focusing on practical, evidence-based strategies to enhance outcomes across the lifespan for individuals living with LGS.

Led by a neurologist, pediatrician, and LGS advocate, this program emphasizes:
  •  Early and accurate seizure identification
  •  Integration of emerging treatments into personalized care plans
  •  Multidisciplinary care coordination and support for family caregivers
  •  Strategies for improving transitions from pediatric to adult care


Participants will engage in small-group breakout sessions to apply what they’ve learned and collaborate on de-identified case studies—strengthening clinical confidence and enhancing shared decision-making in practice.

Target Audience

This activity is designed for neurologists, epileptologists, pediatricians, and allied health professionals involved in the management of patients with Lennox-Gastaut Syndrome (LGS).

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from Jazz Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Summarize the different seizure types in LGS to improve diagnostic accuracy and treatment planning. 
  • Implement strategies to reduce diagnostic delays for LGS, enabling earlier intervention and improved long-term outcomes.
  • Review the mechanisms of action, clinical benefits, and limitations of emerging therapies for LGS, and demonstrate how to integrate them into individualized care plans for optimal patient outcomes. 
  • Apply skills to educate and support caregivers in managing LGS-related challenges, with a focus on behavioral management and cognitive support throughout the care continuum. 

Accredited Provider

This activity is jointly provided by Partners for Advancing Clinical Education and Iridium Continuing Education.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Iridium Continuing Education. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

Partners requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
The planners and managers have the following relevant financial relationships with ineligible companies:

The planners and managers at Partners have no relevant financial relationships to disclose.

The planners and managers at Iridium Continuing Education have no relevant financial relationships to disclose.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Elaine Wirrell, MD
Professor of Neurology, Chair of Child Neurology, Mayo Clinic

Independent Contractor (Including contracted research): Encoded, Grin pharma, Neurocrine
Kelsey Klaas, MD
Assistant Professor of Pediatric and Adolescent Medicine; Medical Co-Director, Pediatric Pain Rehabilitation Center
Disclosures:

Jennifer Griffin
Lennox-Gastaut Syndrome (LGS) Foundation, Director of
Family Support
Nothing to disclose.
Gain practical, caregiver-informed insights from a neurologist, pediatrician, and LGS advocate in this CME-certified, case-based virtual webinar focused on improving recognition, treatment, and family engagement in Lennox-Gastaut Syndrome (LGS).

Join us live on the date that works best for you—each session delivers the same engaging content and interactive learning experience. Sessions include concise expert presentations, powerful patient documentary vignettes, and small-group breakout discussions that promote peer-to-peer exchange and reflection.

This program equips healthcare providers with actionable, evidence-based strategies to support individuals living with LGS and their families across the care continuum—from early childhood through adulthood.

You’ll learn how to:  
  • Enhance early recognition of LGS symptoms and seizure patterns
  • Apply best practices in treatment planning and care transitions
  • Address caregiver burden and family needs through a multidisciplinary lens
 

Participants are encouraged to actively contribute to breakout discussions and may bring de-identified clinical cases to enrich shared learning.

Target Audience

This activity is designed for neurologists, epileptologists, pediatricians, and allied health professionals involved in the management of patients with Lennox-Gastaut Syndrome (LGS).

Dates

Upcoming Accredited LGS CME Sessions with Expert-Led Breakouts:
 
📅 Friday, September 26, 2025 | 4:00 PM ET / 3:00 PM CT / 1:00 PM PT

📅 Wednesday, October 1, 2025 | 5:00 PM ET / 4:00 PM CT / 2:00 PM PT

📅 Thursday, October 9, 2025 | 6:00 PM ET / 5:00 PM CT / 3:00 PM PT

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the webinar
  • Complete the posttest with a score of 70% or higher

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For additional information about the accreditation of this activity, please visit https://partnersed.com

System Requirements

System requirements
This educational activity is supported by an independent educational grant from Jazz Pharmaceuticals.

Maximum Credit Amount: 1.00

Credit Type: ACCME, ANCC
Release: 09/26/2025
Expiration: 10/09/2025

This educational activity is supported by independent educational grants from GSK and Janssen Biotech, Inc administered by Janssen Scientific Affairs, LLC.

Maximum Credit Amount: 4.00

Credit Type: ACCME, ANCC
Release: 04/16/2025
Expiration: 05/21/2026